Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Denali Therapeutics Inc. (DNLI) had Normalized Income after Taxes of $-124.12M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-124.12M |
|
-- |
|
-- |
|
$134.96M |
|
$-134.96M |
|
$10.84M |
|
$-124.12M |
|
$-124.12M |
|
$-124.12M |
|
$-124.12M |
|
$-124.12M |
|
|
Normalized Income after Taxes |
$-124.12M |
$-134.96M |
|
$-134.62M |
|
171.45M |
|
171.45M |
|
$-0.72 |
|
$-0.72 |
|
| Balance Sheet Financials | |
$934.71M |
|
$58.72M |
|
$231.53M |
|
$1.17B |
|
$91.06M |
|
$5.58M |
|
$48.13M |
|
$139.19M |
|
$1.03B |
|
$1.03B |
|
$1.03B |
|
145.69M |
|
| Cash Flow Statement Financials | |
$-206.77M |
|
$176.68M |
|
$-2.14M |
|
$176.53M |
|
$144.31M |
|
$-32.22M |
|
$50.55M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.27 |
|
-- |
|
-- |
|
0.01 |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-216.12M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.09% |
|
-12.09% |
|
-10.64% |
|
-12.02% |
|
$7.05 |
|
$-1.26 |
|
$-1.21 |
|